Having trouble viewing this email? View in your browser.

During the 2021 ECCMID, on July 11th,
ADVANZ PHARMA held a virtual Integrated Symposium on
“PLACE IN THERAPY OF CONTEMPORARY LIPOGLYCOPEPTIDES
AND CEPHALOSPORINS IN AN EVOLVING ENVIRONMENT”
chaired by Prof Soriano and Prof Bonomo (ESCMID appointed-Chair).

If you couldn’t make the live session, you can view
the recordings on-demand by visiting our digital platform
www.advanzdigitalhub.com

TOPICS:

Challenges in antibiotic therapy of Gram-positive
and polymicrobial infections

Prof Stefani / IT

Antibiotic stewardship and tolerability – Implications for the place
in therapy of contemporary Lipoglycopeptides and Cephalosporins

Dr Ritchie / UK

Case reviews – Experience and evidence
for the use of Dalbavancin and Ceftobiprole

Prof Soriano / ES

Update on the management of bacterial coinfections
in Covid-19 patients

Prof Tascini / IT

Real-life pharmaco-economic analysis of Dalbavancin

Dr Béraud & Prof Dinh / FR
ADVANZ DIGITAL HUB Thank you,
ADVANZ PHARMA Anti-infective Team

You have received this email as a contact of ESCMID or one of its affiliated societies. You can unsubscribe or change your newsletter subscriptions here.

This newsletter has been sent to: $$EMAIL$$